# EyePoint, Inc.: financial statements, quarterly

EYPT · Nasdaq · CIK 1314102 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eypt.md) · [Financials](/companies/eypt/financials.md) · [Filings](/companies/eypt/filings.md) · [Insiders](/companies/eypt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/eypt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [15.2](/filings/0000950170-24-123267.md) | [14.0 d](/filings/0000950170-25-034601.md) | [11.7](/filings/0000950170-25-066907.md) | [9.5](/filings/0001193125-25-175418.md) | [10.5](/filings/0001193125-25-269471.md) | [11.6 d](/filings/0001193125-26-093917.md) | [24.5](/filings/0001193125-26-211870.md) | [5.3](/filings/0001193125-26-335037.md) | [1.0](/filings/0001193125-25-269471.md) | [0.6 d](/filings/0001193125-26-093917.md) | [0.7](/filings/0001193125-26-211870.md) | [0.5](/filings/0001193125-26-335037.md) |
| Cost of revenue | $m | [1.2](/filings/0000950170-24-123267.md) | not reported | [0.8](/filings/0000950170-24-056380.md) | [1.4](/filings/0000950170-24-093853.md) | [0.7](/filings/0000950170-24-123267.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [17.4](/filings/0000950170-24-123267.md) | [18.0 d](/filings/0000950170-25-034601.md) | [30.1](/filings/0000950170-25-066907.md) | [29.8](/filings/0001193125-25-175418.md) | [29.5](/filings/0001193125-25-269471.md) | [43.4 d](/filings/0001193125-26-093917.md) | [58.6](/filings/0001193125-26-211870.md) | [55.5](/filings/0001193125-26-335037.md) | [47.8](/filings/0001193125-25-269471.md) | [59.2 d](/filings/0001193125-26-093917.md) | [72.1](/filings/0001193125-26-211870.md) | [83.6](/filings/0001193125-26-335037.md) |
| Operating income | $m | [(14.4)](/filings/0000950170-24-123267.md) | [(16.4) d](/filings/0000950170-25-034601.md) | [(33.3)](/filings/0000950170-25-066907.md) | [(34.5)](/filings/0001193125-25-175418.md) | [(32.7)](/filings/0001193125-25-269471.md) | [(45.2) d](/filings/0001193125-26-093917.md) | [(48.8)](/filings/0001193125-26-211870.md) | [(62.2)](/filings/0001193125-26-335037.md) | [(62.0)](/filings/0001193125-25-269471.md) | [(70.3) d](/filings/0001193125-26-093917.md) | [(87.2)](/filings/0001193125-26-211870.md) | [(97.4)](/filings/0001193125-26-335037.md) |
| Interest expense | $m | [0.0](/filings/0000950170-23-058775.md) | [0.0 d](/filings/0000950170-24-028523.md) | [0.0](/filings/0000950170-24-056380.md) | [0.0](/filings/0000950170-24-093853.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | [0.0](/filings/0001193125-25-175418.md) | [0.0](/filings/0001193125-25-269471.md) | [0.1 d](/filings/0001193125-26-093917.md) | [0.0](/filings/0001193125-26-211870.md) | [0.1](/filings/0001193125-26-335037.md) | [0.0](/filings/0001193125-25-269471.md) | [0.2 d](/filings/0001193125-26-093917.md) | [(0.1)](/filings/0001193125-26-211870.md) | [0.0](/filings/0001193125-26-335037.md) |
| Net income | $m | [(12.6)](/filings/0000950170-24-123267.md) | [(14.1) d](/filings/0000950170-25-034601.md) | [(29.3)](/filings/0000950170-25-066907.md) | [(30.8)](/filings/0001193125-25-175418.md) | [(29.4)](/filings/0001193125-25-269471.md) | [(41.4) d](/filings/0001193125-26-093917.md) | [(45.2)](/filings/0001193125-26-211870.md) | [(59.4)](/filings/0001193125-26-335037.md) | [(59.7)](/filings/0001193125-25-269471.md) | [(67.6) d](/filings/0001193125-26-093917.md) | [(84.8)](/filings/0001193125-26-211870.md) | [(94.5)](/filings/0001193125-26-335037.md) |
| Diluted EPS | $ per share | [(0.33)](/filings/0000950170-24-123267.md) | not reported | [(0.55)](/filings/0000950170-25-066907.md) | [(0.58)](/filings/0001193125-25-175418.md) | [(0.54)](/filings/0001193125-25-269471.md) | not reported | [(0.65)](/filings/0001193125-26-211870.md) | [(0.85)](/filings/0001193125-26-335037.md) | [(0.85)](/filings/0001193125-25-269471.md) | not reported | [(0.99)](/filings/0001193125-26-211870.md) | [(1.09)](/filings/0001193125-26-335037.md) |
| Basic EPS | $ per share | [(0.33)](/filings/0000950170-24-123267.md) | not reported | [(0.55)](/filings/0000950170-25-066907.md) | [(0.58)](/filings/0001193125-25-175418.md) | [(0.54)](/filings/0001193125-25-269471.md) | not reported | [(0.65)](/filings/0001193125-26-211870.md) | [(0.85)](/filings/0001193125-26-335037.md) | [(0.85)](/filings/0001193125-25-269471.md) | not reported | [(0.99)](/filings/0001193125-26-211870.md) | [(1.09)](/filings/0001193125-26-335037.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [133](/filings/0000950170-24-123267.md) | [281](/filings/0000950170-25-034601.md) | [271](/filings/0000950170-25-066907.md) | [90.8](/filings/0001193125-25-175418.md) | [79.8](/filings/0001193125-25-269471.md) | [99.7](/filings/0001193125-26-093917.md) | [85.2](/filings/0001193125-26-211870.md) | [71.1](/filings/0001193125-26-335037.md) | [74.6](/filings/0001193125-25-269471.md) | [102](/filings/0001193125-26-335037.md) | [77.7](/filings/0001193125-26-211870.md) | [110](/filings/0001193125-26-335037.md) |
| Current assets | $m | [150](/filings/0000950170-23-058775.md) | [345](/filings/0000950170-25-034601.md) | [318](/filings/0000950170-24-056380.md) | [295](/filings/0000950170-24-093853.md) | [269](/filings/0000950170-24-123267.md) | [383](/filings/0001193125-26-093917.md) | [327](/filings/0000950170-25-066907.md) | [265](/filings/0001193125-25-175418.md) | [216](/filings/0001193125-25-269471.md) | [329](/filings/0001193125-26-335037.md) | [250](/filings/0001193125-26-211870.md) | [189](/filings/0001193125-26-335037.md) |
| Total assets | $m | [160](/filings/0000950170-23-058775.md) | [355](/filings/0000950170-25-034601.md) | [329](/filings/0000950170-24-056380.md) | [324](/filings/0000950170-24-093853.md) | [301](/filings/0000950170-24-123267.md) | [418](/filings/0001193125-26-093917.md) | [363](/filings/0000950170-25-066907.md) | [301](/filings/0001193125-25-175418.md) | [252](/filings/0001193125-25-269471.md) | [364](/filings/0001193125-26-335037.md) | [288](/filings/0001193125-26-211870.md) | [228](/filings/0001193125-26-335037.md) |
| Current liabilities | $m | [63.9](/filings/0000950170-23-058775.md) | [63.3](/filings/0000950170-25-034601.md) | [62.6](/filings/0000950170-24-056380.md) | [62.1](/filings/0000950170-24-093853.md) | [48.8](/filings/0000950170-24-123267.md) | [49.0](/filings/0001193125-26-093917.md) | [41.7](/filings/0000950170-25-066907.md) | [33.2](/filings/0001193125-25-175418.md) | [30.1](/filings/0001193125-25-269471.md) | [37.0](/filings/0001193125-26-335037.md) | [37.5](/filings/0001193125-26-211870.md) | [41.9](/filings/0001193125-26-335037.md) |
| Total liabilities | $m | [101](/filings/0000950170-23-058775.md) | [88.9](/filings/0000950170-25-034601.md) | [79.3](/filings/0000950170-24-056380.md) | [95.9](/filings/0000950170-24-093853.md) | [82.2](/filings/0000950170-24-123267.md) | [82.0](/filings/0001193125-26-093917.md) | [64.2](/filings/0000950170-25-066907.md) | [55.1](/filings/0001193125-25-175418.md) | [51.5](/filings/0001193125-25-269471.md) | [57.9](/filings/0001193125-26-335037.md) | [57.7](/filings/0001193125-26-211870.md) | [61.8](/filings/0001193125-26-335037.md) |
| Long-term debt | $m | [0.0](/filings/0000950170-23-058775.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [0.0](/filings/0000950170-23-058775.md) | [0.0](/filings/0000950170-24-028523.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [58.6](/filings/0000950170-24-123267.md) | [266](/filings/0001193125-26-093917.md) | [250](/filings/0001193125-25-175418.md) | [228](/filings/0001193125-25-269471.md) | [219](/filings/0001193125-25-269471.md) | [337](/filings/0001193125-26-335037.md) | [298](/filings/0001193125-26-335037.md) | [246](/filings/0001193125-26-335037.md) | [200](/filings/0001193125-25-269471.md) | [306](/filings/0001193125-26-335037.md) | [230](/filings/0001193125-26-335037.md) | [166](/filings/0001193125-26-335037.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(15.2) d](/filings/0000950170-24-123267.md) | [(23.1) d](/filings/0000950170-25-034601.md) | [(31.2)](/filings/0000950170-25-066907.md) | [(20.2) d](/filings/0001193125-25-175418.md) | [(39.0) d](/filings/0001193125-25-269471.md) | [(35.8) d](/filings/0001193125-26-093917.md) | [(53.1)](/filings/0001193125-26-211870.md) | [(62.6) d](/filings/0001193125-26-335037.md) | [(59.4) d](/filings/0001193125-25-269471.md) | [(65.0) d](/filings/0001193125-26-093917.md) | [(80.5)](/filings/0001193125-26-211870.md) | [(62.3) d](/filings/0001193125-26-335037.md) |
| Capital expenditure | $m | [1.7 d](/filings/0000950170-24-123267.md) | [0.9 d](/filings/0000950170-25-034601.md) | [1.2](/filings/0000950170-25-066907.md) | [0.9 d](/filings/0001193125-25-175418.md) | [1.6 d](/filings/0001193125-25-269471.md) | [0.4 d](/filings/0001193125-26-093917.md) | [0.3](/filings/0001193125-26-211870.md) | [1.2 d](/filings/0001193125-26-335037.md) | [0.8 d](/filings/0001193125-25-269471.md) | [1.0 d](/filings/0001193125-26-093917.md) | [1.0](/filings/0001193125-26-211870.md) | [1.2 d](/filings/0001193125-26-335037.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [37.3](/filings/0000950170-23-058775.md) | [0.0](/filings/0000950170-24-056380.md) | [37.6](/filings/0000950170-24-093853.md) | [38.3](/filings/0000950170-24-123267.md) | [52.9](/filings/0000950170-25-066907.md) | [0.1](/filings/0001193125-25-175418.md) | [0.1](/filings/0001193125-25-269471.md) | [0.1](/filings/0001193125-26-211870.md) | [0.1](/filings/0001193125-26-335037.md) | [0.1](/filings/0001193125-25-269471.md) | [0.1](/filings/0001193125-26-211870.md) | [0.1](/filings/0001193125-26-335037.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 86,212,138 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335037.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.